- John Orloff, M.D. Appointed Head of Research and Development -
- Anne-Marie Law Joins as Chief Human Resources Officer -
- Indrani Franchini Joins as Chief Compliance Officer -
NEW HAVEN, Conn.--(BUSINESS WIRE)--
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) today announced key additions
to its executive leadership team effective June 5, 2017. Reporting to
Chief Executive Officer, Ludwig Hantson will be: John Orloff, M.D.,
Executive Vice President, Head of Research & Development, Anne-Marie
Law, Executive Vice President, Chief Human Resources Officer, and
Indrani Lall Franchini, J.D., Executive Vice President, Chief Compliance
"I am delighted to welcome John, Anne-Marie, and Indrani to Alexion.
Each of these highly talented executives brings deep industry experience
and a proven track record in their respective areas of expertise," said
Ludwig Hantson, Chief Executive Officer of Alexion. "These experienced
leaders join our team of exceptionally skilled and dedicated employees
around the world and will be key partners as we build upon Alexion's
solid foundation to drive continued growth and deliver long-term value
for all of our stakeholders."
John Orloff, M.D., Head of Research & Development
Dr. Orloff is a global R&D business leader with 20 years of experience
in the biopharmaceutical industry and deep expertise spanning various
stages of clinical and non-clinical development, including developing
medicines for rare diseases. As Alexion's Head of R&D, Dr. Orloff will
be focused on strengthening the Company's clinical pipeline and research
programs, enhancing R&D productivity, overseeing regulatory and medical
affairs, and supporting business development. Dr. Martin Mackay,
Alexion's current Head of R&D, will work with Dr. Orloff to ensure a
smooth transition of Alexion's key pipeline programs, including the
registration filings of Soliris® (eculizumab) for patients
with refractory generalized myasthenia gravis (gMG) and the ALXN1210
clinical development programs.
"John's experience in successfully developing biopharmaceuticals,
including in the areas of hematology, immunology, and metabolics, as
well his strong global clinical and regulatory expertise, makes him
ideally suited to lead the R&D function at Alexion. John and I are
aligned on the highest priority development programs, including the gMG
registration filings and the ALXN1210 development programs. I'm pleased
to work with John again and know him as a leader who fosters effective
teams and drives innovation on a global scale to serve the needs of
patients," said Dr. Hantson.
Dr. Orloff joins Alexion from Novelion where he served as Executive Vice
President, Head of Research & Development since November 2016.
Previously, he was Global Head of R&D and Chief Scientific Officer at
Baxalta, where he advanced the company's pipeline and oversaw regulatory
approval of 10 unique products and two devices over two years. He also
held executive R&D roles with Baxter International, Merck Serono,
Novartis and Merck Research Laboratories. Prior to joining the
biopharmaceutical industry in 1997, Dr. Orloff was with Yale University
School of Medicine for seven years. He received his A.B. from Dartmouth
College and his M.D. from the University of Vermont College of Medicine,
and he completed his medical training at the University of Pittsburgh
Medical Center and Yale University School of Medicine.
Anne-Marie Law, Chief Human Resources Officer
Ms. Law is a human resources executive with more than 25 years of
experience at global corporations with a strong track record of driving
positive change and managing multi-national workforces in multiple
global locations. As Alexion's Chief Human Resources Officer, she will
be focused on building the organizational capabilities to advance
Dr. Hantson stated, "I am very pleased to once again be partnering with
Anne-Marie. She brings to Alexion a strong track record of driving
positive change at global corporations and is recognized for delivering
high-performance, purpose-driven organizations by building diverse,
inclusive, and aligned teams."
Ms. Law joins Alexion from Hyatt Hotels Corporation where she served as
Chief Human Resources Officer responsible for building the strategy to
support the company's 100,000 employees worldwide, and designing talent
systems to create world class leadership and customer connectivity
capabilities. Before joining Hyatt in 2016, Ms. Law served as Executive
Vice President and Head of Human Resources for Baxalta Incorporated, and
held various senior human resources positions at McKesson Corporation,
including the Specialty Health Division, VeriSign, and Xilinx, Inc. Ms.
Law is a graduate of Leicester University with a degree in Art History
in the United Kingdom and The National College of Ireland, Dublin.
Indrani Lall Franchini, J.D., Chief Compliance Officer
Ms. Franchini has extensive experience developing and building the
infrastructure and company-wide standards for global compliance
programs, interacting with regulatory agencies and establishing
multi-functional teams to support global compliance programs. As
Alexion's Chief Compliance Officer, Ms. Franchini will be focused on
enhancing Alexion's global compliance program, ensuring it meets all
legal and regulatory requirements and industry guidelines while
protecting the value the Company brings to patients, the community, and
external stakeholders. She will also co-lead the Company's newly formed
Global Corporate Compliance Committee.
"As we continue to grow worldwide to best serve patients, our commitment
to compliance and performing with integrity has never been greater.
Given that compliance and growth go hand-in-hand, Indrani, with her
global biopharmaceutical experience and by partnering with colleagues
across the Company, will ensure that everywhere we do business not only
complies with applicable laws and regulations but also meets Alexion's
high ethical standards," commented Dr. Hantson.
Ms. Franchini joins Alexion from Hess Corporation where she served as
Chief Compliance Officer. Before joining Hess in 2012, Ms. Franchini
spent nearly ten years with Pfizer, most recently as Chief Compliance
Counsel for its Pharmaceutical Business, overseeing all compliance
elements for the development, marketing, and promotion of this global
business. Earlier in her career, Ms. Franchini served as an attorney
with Milbank, Tweed, Hadley & McCloy in the firm's New York and Tokyo
offices. Ms. Franchini earned her J.D. from the University of Michigan
Law School and her B.A. from Princeton University. In addition, she
spent a year as a Fulbright Fellow at the Kyushu University Graduate
School in Fukuoka, Japan.
Alexion is a global biopharmaceutical company focused on developing and
delivering life-transforming therapies for patients with devastating and
rare disorders. Alexion is the global leader in complement inhibition
and has developed and commercializes the first and only approved
complement inhibitor to treat patients with paroxysmal nocturnal
hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two
life-threatening ultra-rare disorders. In addition, Alexion's metabolic
franchise includes two highly innovative enzyme replacement therapies
for patients with life-threatening and ultra-rare disorders,
hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).
Alexion is advancing its rare disease pipeline with highly innovative
product candidates in multiple therapeutic areas. This press release and
further information about Alexion can be found at: www.alexion.com.
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements often include words such as "anticipate,"
"believe," "expect," "will," or similar expressions. Forward-looking
statements are subject to factors that may cause Alexion's results and
plans to differ from those expected, including for example, risks
related to potential disruptions to our business as a result of
leadership changes, and a variety of other risks set forth from time to
time in Alexion's filings with the U.S. Securities and Exchange
Commission, including but not limited to the risks discussed in
Alexion's Quarterly Report on Form 10-Q for the period ended March 31,
2017 and in our other filings with the U.S. Securities and Exchange
Commission. Alexion does not intend to update any of these
forward-looking statements to reflect events or circumstances after the
date hereof, except when a duty arises under law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170601006463/en/
Alexion Pharmaceuticals Inc.
Executive Director, Corporate Communications
Ridloff, CFA, 475-230-3601
Vice President, Investor Relations
Director, Investor Relations
Source: Alexion Pharmaceuticals Inc.
News Provided by Acquire Media